Drug approvals: the review clock decides more markets than the data does

Two application types carry almost everything traded here. A new drug application covers conventional small molecules; a biologics license application covers biologics, which since 2020 includes peptides above a certain length - a reclassification that quietly moved several metabolic drugs from one pathway to the other. Both run on the same review goals, so for pricing purposes the distinction matters mainly because it tells you which of the agency's centres owns the file.

The decision itself has exactly two outcomes and they are frequently misdescribed. The agency either approves, or it issues a complete response letter setting out what would need to change. There is no rejection in the sense the word implies: a complete response letter is a list of deficiencies and an invitation to resubmit, and a substantial share of drugs that receive one are approved later. Coverage reports it as a failure because the share price behaves like one.

What is emphatically not being decided is whether the drug works. Efficacy is one input among several, and applications with unambiguous trial results are turned back over manufacturing inspections, facility findings at a contract producer, or chemistry and controls data that has nothing to do with the patient. A trader with a strong view on the trial and no view on the plant has an incomplete position.

An approval decision is one of the few corporate events with a publicly known target date attached months in advance. The company discloses the submission, the agency sets a goal date, and the company discloses that too, because it is material. That gives a market something almost nothing else in this library has: a scheduled binary with a knowable deadline.

It is also unusually consequential per event. For a company whose value rests on one asset, an approval and a complete response letter are separated by a large fraction of market capitalisation, and the move happens in a single session. That combination - a scheduled date and a large discrete move - is why these markets exist at all and why they attract informed flow.

The board reflects that. Beyond individual drugs, the 2026 inventory carries contracts on a skin cancer vaccine both at the submission stage and at approval, on approval of a type 1 diabetes cure across a multi-year horizon, on MDMA for PTSD, and on who will be named to run the agency - which is a different question about the same institution and resolves on an announcement rather than a review.

The agency does not publish a calendar of pending decisions. Almost every goal date in circulation is disclosed by the company - in a press release, an earnings call or a securities filing - because a pending regulatory decision is material information. That means the primary source for a date is the sponsor's own investor relations page, and the aggregated calendars that circulate are secondary compilations of those disclosures with the usual transcription risk.

Two agency-side facts are published and both are useful. The applicant is told within sixty days of receipt whether the review is priority or standard, and priority designation carries a defined meaning: the product would offer a significant improvement in the safety or effectiveness of prevention, diagnosis or treatment of a serious condition compared with available drugs. The designation therefore does double duty - it moves the date forward by four months and it tells you how the agency currently frames the product.

Advisory committee meetings are announced in advance in the Federal Register, along with the agency's own briefing documents, which are typically posted two days before the meeting. Those documents are the single most information-dense artefact in the whole process and they are free. They regularly move a price more than the meeting itself does.